Correction to: Scientific Reports https://doi.org/10.1038/s41598-022-22410-x, published online 17 October 2022

The original version of this Article contained errors.

As a result of an error during assembly of Figure 4A, two mice representing the shNon control were duplicated from the shASPP2+BBR condition. As a result, the corresponding bioluminescence statistical analysis was also incorrect. The original Figure 4 and accompanying legend appears below.

Fig. 4
figure 4

Inhibition of cholesterol biosynthesis suppresses lung metastasis of breast cancer in LPS-stimulated mice. (a) Female BALB/c mice were intraperitoneally injected with LPS for 6 h before luciferase expressing 4T1 (1 × 106) cells were injected through the tail vein. Inducible shRNA-luc expressing 4T1 cells were monitored by BLI every 3 days. Simvastatin, BBR or DNase I treatment was initiated after randomization on day 5 (n = 5 mice per group; means ± SD). Representative BLI images at day 25. The densities of BLI images were calculated and statically analyzed. (b) Representative H&E images of the lung metastases in LPS-stimulated mouse model. (n = 10 each). Lung metastatic burdens were assessed by comparing metastatic area to total lung area. Scare bar: 200 µm. (c) Mice are bled from the retro-orbital venous plexus on day 24, and serums are collected. Cholesterol levels are determined and statically analyzed. *P < 0.05; **P < 0.01; ***P < 0.001.

Full size image

In addition, as a result of an error during the assembly of Figure 8A, the CCDC25 immunohistochemical staining panel from Case 2 (without metastases) was duplicated from Case 4 (breast metastases). The original Figure 8 and accompanying legend appears below.

Fig. 8
figure 8

Tissue microarray staining and statistical analysis. (a) CCDC25, H3cit and HMGCR were detected by immunohistochemical staining in a tissue microarray containing 60 breast tissues. Representative pictures of IHC staining in normal or papacancerous breast tissues, primary breast cancer tissues, and metastatic tissues. Scale bars: 200 µm. (b) Statistical analyses of the correlations between HMGCR and CCDC25, HMGCR and H3cit, CCDC25 and H3cit, according to immunohistochemical scoring by Fisher’s test. (c) Statistical analyses IHC score of HMGCR, CCDC25 and H3cit in normal tissues, primary breast cancer tissues and metastatic tissues by Two-way ANOVA test. (d) Kaplan–Meier curves showing the overall survival of patients with breast cancer with high or low CCDC25 and HMGCR expression in The Cancer Genome Atlas (TCGA) breast cancer online database (n = 176). Comparisons were performed using a log rank test. P < 0.05; **P < 0.01; ***P < 0.001. (e) The schematic model depicts how cholesterol biosynthesis contributes to CCDC25 expression, NETs formation and distant metastases.

Full size image

The original Article has been corrected.